Dr Reddys Laboratories launches Deferasirox Tablets for Oral Suspension

Dr Reddys Laboratories announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade (deferasirox) Tablets for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).

The Exjade brand had U.S. sales of approximately $113 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health.

Dr Reddys Deferasirox Tablets for Oral Suspension, are available in 125 mg, 250 mg, and 500 mg dosage strengths in bottle count sizes of 30.

Powered by Capital Market - Live News